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Abstract
Background: Microarray gene-profiling of invasive breast cancer has identified different subtypes including luminal
A, luminal B, HER2-overexpressing and basal-like groups. Basal-like invasive breast cancer is associated with a worse
prognosis. However, the prognosis of basal-like ductal carcinoma in situ (DCIS) is still unknown. Our aim was to
study the prognosis of basal-like DCIS in a large population-based cohort.
Methods: All 458 women with a primary DCIS diagnosed between 1986 and 2004, in Uppland and Västmanland,
Sweden were included. TMA blocks were constructed. To classify the DCIS tumors, we used immunohistochemical
(IHC) markers (estrogen-, progesterone-, HER2, cytokeratin 5/6 and epidermal growth factor receptor) as a surrogate
for the gene expression profiling. The association with prognosis was examined for basal-like DCIS and other
subtypes using Kaplan-Meier survival analyses and Cox proportional hazards regression models.
Results: IHC data were complete for 392 women. Thirty-two were basal-like (8.2%), 351 were luminal or HER2-
positive (89.5%) and 9 unclassified (2.3%). Seventy-six women had a local recurrence of which 34 were invasive.
Another 3 women had general metastases as first event. Basal-like DCIS showed a higher risk of local recurrence
and invasive recurrence 1.8 (Confidence interval (CI) 95%, 0.8-4.2) and 1.9 (0.7-5.1), respectively. However, the
difference was not statistically significant. Also, no statistically significant increased risk was seen for triple-negative
or high grade DCIS.
Conclusions: Basal-like DCIS showed about a doubled, however not statistically significant risk for local recurrence
and developing invasive cancer compared with the other molecular subtypes. Molecular subtyping was a better
prognostic parameter than histopathological grade.
Background
Increased use of screening mammography, beginning in
the early 1980 s, has resulted in a dramatic increase in
detection of ductal carcinoma in situ (DCIS). DCIS is a
pre-invasive disease with a clinically and molecularly
heterogeneous presentation that poses a major challenge
in both diagnosis and treatment [1-3]. A clinically
accepted classification system predicting prognosis is
still missing.
Recently, the idea of using molecular subtyping to pre-
dict the prognosis of invasive breast cancer has been
widely accepted [4-8]. The introduction of high-
throughput DNA microarray technologies marked an
entirely new era of genome-wide approaches to predict
prognosis and outcome [9,10]. According to similarities
in gene expression characteristics, Perou et al., [11] crea-
tively classified breast cancer into five subtypes: luminal
A, luminal B, basal like, HER2-positive and normal-like.
Molecular subtypes have been shown to have prognostic
and treatment predictive value. Among those, the basal-
like tumors are characterized as expressing genes related
to myoepithelial cells [12]. Follow-up studies have
shown that basal-like cancer is associated with a higher
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any medium, provided the original work is properly cited.risk of disease recurrence, distant metastasis and shorter
survival. The poorer outcome of patients with basal-like
tumors has been shown in different patient populations
[13-17]. However, the prognosis of basal-like DCIS still
unknown.
In this study, our aim was to investigate the prognosis
of basal-like DCIS compared to other subtypes in a
large population-based cohort. To classify the DCIS
tumors, we used immunohistochemical (IHC) markers
that have previously been used as a surrogate marker
for the gene expression profiles [16-21]. Livasy et al.,
have earlier shown that IHC can be used for the identi-
fication of basal like DCIS [18]. We identified the sub-
types of DCIS in tumors from a cohort of 458 women
with tumor material assembled in tissue micro arrays
(TMA) [22]. To our knowledge, this study is the first to
examine the prognosis of DCIS in relation to different
molecular subtypes defined by IHC.
Methods
Patients
We recruited all 458 women who were diagnosed with a
primary DCIS between 1986 and 2004 in Uppland and
Västmanland, Sweden.
TMA construction
H&E sections from all eligible cases were reviewed to
select the area from which the cores for the TMAs would
be taken. Prior to the TMA construction, all primary
DCIS cases were histopathologically re-evaluated by one
pathologist (KJ). Two cores of 1.0 mm in diameter were
mounted into the recipient TMA blocks using a manual
arraying device (MTA-1, Beecher Inc, WI, USA). The
concordance of IHC staining between original whole sec-
tion slides and TMA-slides and between biopsies from
the same lesion in DCIS has earlier been evaluated in a
subset of the cohort [23,24]. In total, ten TMA blocks
were constructed from 458 cancer samples.
IHC and silver-enhanced in situ hybridization (SISH)
We performed IHC for estrogen receptor (ER), proges-
terone receptor (PR), human epidermal growth factor
receptor 2 (HER2), cytokeratin 5/6 (CK5/6) and epider-
mal growth factor receptor (EGFR) on 4 μm paraffin
sections cut from the TMAs. Immunostains for each
marker were performed on a Dako Autostainer (Dako
Corporation). IHC was conducted according to estab-
lished protocols. Appropriate positive and negative con-
trols were included in all staining runs.
HER2 SISH was performed on an automated instru-
ment, Ventana Benchmark (Ventana Medical Systems,
Tucson, AZ), as per the manufacturer’sp r o t o c o l sf o r
the INFORM HER2 DNA probe and chromosome
17 probes. Testing for the HER2 gene and chromosome
17 was performed on sequential sections. Both probes
are labeled with dinitrophenol. Denaturation occurred
on the instrument with enzyme digestion in protease 3
for 8 minutes. The detection system used a multimer
labeled with goat antirabbit antibody horseradish peroxi-
dase as the linking step. Visualization occurred with the
sequential addition of silver acetate as the source of
ionic silver, hydroquinone, and hydrogen peroxide to
give a black metallic silver precipitate at the probe site.
Counterstaining was performed with hematoxylin II on
the instrument. The time taken for the complete run is
6.5 hours. Both HER2 and chromosome 17 detection
were performed on the same slide run. Gene amplifica-
tion was assessed using the American Society of Clinical
Oncology/College of American Pathologists guideline
and Australian HER2 Advisory Board criteria for single
HER2 probe testing (diploid, 1 to 2.5 copies/nucleus;
polysomy >2.5 to 4 copies/nucleus; equivocal, >4 to 6
copies/nucleus; low-level amplification, >6 to 10 copies/
nucleus; and high-level amplification >10 copies/
nucleus) and for dual HER2/CHR17 probe testing (non-
amplified ratio <1.8; equivocal ratio, 1.8 to 2.2; gene
amplification, >2.2). The status of HER2 protein expres-
sion was assessed relying on SISH. For those cases on
which SISH failed, the expression was based on IHC.
Scoring and classification
Stained TMA slides were scanned (ScanScope® XT,
Aperio, USA) for evaluation of expression of ER, PR,
HER2, CK5/6 and EGFR by ImageScope (Aperio, USA).
Tumor cells that showed nuclear staining for ER or PR
(> 10% of tumor cell nuclei staining) were considered
ER or PR-positive respectively. Using the HerceptTest™-
classification system, tumors were considered HER2
positive if the score was 3+. Cases were considered CK
5/6-positive or EGFR-positive if any cytoplasmic and/or
membranous staining was detected in the tumor cells,
even if focal. These latter IHC criteria are similar to
those previously used for scoring these markers in inva-
sive breast cancers [18,22,25,26]. If only one core
included enough tumor tissue this was used for classifi-
cation but at least 200 cells had to be present. Each
tumor marker was scored by one single observer; ER,
PR and HER2 by WZ, EGFR and CK5/6 by CJ and SISH
by RMA.
For this study, the IHC subtype definitions used were
the refined definitions used in the analysis of invasive
breast cancer: basal-like (ER-, HER2-, EGFR+ and/or
cytokeratin 5/6+) [17]. Cases classified as negative for all
t h ea b o v em a r k e r sw e r ed e f i n e da su n c l a s s i f i e di st h i s
study. Cases with missing data, due to lack of tumor
tissue in the TMAs, were excluded from the further
analyses. In the survival analyses we compared the
basal-like group with all other DCIS together.
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Follow-up started on the day of diagnosis and concluded
on the date the patient was last observed or the date of
death. The database was frozen for the statistical ana-
lyses based on follow-up through 30th April 2008. Com-
plete follow-up was achieved for all 458 patients.
For this study, the two primary end points were local
recurrence and invasive- or general recurrence. Local
recurrence was defined as any ipsilateral recurrence (in
situ or invasive). In addition, we defined “invasive- or
general recurrence” as occurrence of an invasive ipsilat-
eral recurrence, general metastasis or breast cancer-
specific death, whichever occurred first. All women with
an invasive local recurrence were included as cases regard-
ing both endpoints. The endpoint “invasive- or general
recurrence” was constructed to find patients with a biolo-
gically more aggressive disease. Contralateral breast
tumors were considered as new primary breast cancers.
Statistic analyses
Baseline characteristics among patients with different
molecular subtypes were compared by Chi-square for
categorical variables or analysis of variance for continu-
ous variables. Survival and probabilities of local recur-
rence and invasive disease among patients with different
molecular subtypes were first compared by the Kaplan-
Meier method. Cox proportional hazards regression
models were used to calculate hazard ratios (HRs) with
95% confidence intervals (CIs), with adjustment for age
in the univariate analysis and further, histological grade,
type of surgery, tumor size, detection mode and post-
operative radiotherapy in the multivariate analysis.
Kaplan-Meier curves and Cox proportional hazard mod-
els were used to assess the association between molecu-
lar subgroup and progression of breast cancer. Data
were analyzed using the SAS (SAS Institute, Cary, NC)
and R softwares.
This study was approved by the Ethics Committee at
Uppsala University Hospital (Dnr 2005: 118). In this ret-
r o s p e c t i v ec o h o r ts t u d yw ed i dn o th a v et og e ta n
informed consent from the women according to the
ethical approval, Dnr 170/95 and 99/422.
Results
1. Baseline Characteristics
Baseline characteristics according to the molecular sub-
type of 392 eligible study participants (66 women did
not get enough IHC information) are presented in
Table 1. The median follow-up was 122 months (range
3-130). Among the 392 women, 32 (8.2%) were classi-
fied as basal-like, 351 (89.5%) as luminal or HER2-
positive, and 9 (2.3%) were unclassified. The median age
at diagnose was 58 years (range 30-90 years). All basic
characteristics, including age, tumor size and grade,
were evenly distributed between the basal-like and non
basal-like tumors. No women received antiestrogen or
chemotherapy after primary surgery. Type of surgery,
mastectomy vs. breast conserving surgery (BCS) and
postoperative radiotherapy were decided according to
local tradition. BCS in Sweden means removing a sector
of the breast parenchyma in up to a quadrant of the
breast, aiming for a 10 mm free margin. The breast par-
enchyma is removed from behind the areola margin to
the periphery of the gland. Postoperative radiotherapy
was given to 140 of 298 women undergoing BCS. It was
generally given at 25 occasions, up to 50 Grey. A small
part of these women were included in a Swedish study
randomizing between radiotherapy or not after BCS for
a primary DCIS [27]. Others were given radiotherapy
based on tumor size and histopathological grade. How-
ever, at that time, no criteria for radiotherapy regarding
size or grade were given in the Swedish National
Guidelines.
2. Survival Outcomes
2.1 Local-recurrence
Of the 76 women who had a local recurrence, 42 had an
in situ recurrence and 34 an invasive recurrence. Med-
ian follow-up to local recurrence was 97.5 months
(range 3-255). In both the univariate and multivariate
models, basal-like DCIS showed a higher risk of local
recurrence compared with non basal-like DCIS, hazard
ratio (HR), 1.7 (CI 95%: 0.8-3.8) and 1.8 (0.8-4.2) respec-
tively (Table 2). However, the difference was not statisti-
cally significant. When only looking at women who had
BCS, the risk for basal-like DCIS was equally higher
(Table 2). Kaplan-Meier analyses were also made for all
women and those undergoing BCS separately. The ana-
lyses showed a higher risk for basal-like DCIS compared
to the non basal-like group but it was not statistically
significant. The p-value was 0.08 for all women and 0.26
for women undergoing BCS (Figure 1a).
2.2 Invasive- or general recurrence
Forty-seven women developed invasive disease. Forty-
four had an invasive local recurrence (of which 10 first
had an in situ local recurrence and then an invasive
local recurrence). Three women had general metastases
as the first event. Eight died from breast cancer, but all
of these had had a local recurrence or general metas-
tases before death. Median follow-up to an invasive- or
general recurrence was 111.5 months (range 3-255).
Basal-like DCIS showed a higher risk of invasive- or
general recurrence compared with non basal-like DCIS,
HR, 2.0 (CI 95%: 0.8-5.0) and 1.9 (0.7-5.1) respectively
(Table 2). However, the difference was not statistically
significant. When only looking at women who had BCS,
the risk for basal-like DCIS was also about doubled, but
the risk was not statistically significant higher (Table 2).
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higher risk for invasive- or general recurrence for the
basal-like DCIS (p = 0.15) as seen in Figure 1b and the
p-value for women undergoing BCS was 0.16.
2.3 Triple-negative group vs. non triple-negative group
We also assessed the prognostic implications of
triple-negative (ER-, PR- and HER2-negative) vs. non
triple-negative DCIS. Of all 458 women, 409 could be
classified. Thirty two were classified as triple-negative
and 377 as not. Triple-negative tumors had a HR of 1.1
(95% CI, 0.4-2.7) and 1.1 (0.4-2.9) for local recurrence
compared with the non triple-negative in the univariate
and multivariate analyses, respectively. The adjusted HR
for an invasive- or general recurrence in the triple-nega-
tive group compared with women in non triple-negative
was 1.4 (0.5-4.0) and 1.6 (0.6-4.8).
Kaplan-Meier analyses showed no statistically signifi-
cantly higher risk for local recurrence or invasive- or
general recurrence for the triple-negative DCIS, neither
in the subset of women undergoing BCS (p = 0.86 and
0.25 respectively) nor including all women (p = 0.67 and
0.44 respectively). (Table 2 and Figure 2a-b).
Of the 392 women with complete IHC data, 32 were
classified as basal-like and 32 as triple-negative. How-
ever, only 24 women were classified as both basal-like
and triple-negative. These subgroups were too small to
do any statistical analyses on but during the follow-up,
the 8 women who were basal-like and non triple-
negative had four invasive- or general recurrences and
the 8 women who were triple-negative and non basal-
like only had one invasive recurrence.
Discussion
We have conducted a population-based study of primary
DCIS to assess the association between an IHC surro-
gate basal-like DCIS genotype and prognosis. Our
results showed that basal-like DCIS had a higher risk of
local recurrence and a higher risk of developing invasive
cancer compared to other DCIS. The risk was almost
doubled but this was not statistically significant.
In our study, we defined basal-like DCIS as those that
were ER-negative, HER2-negative, but positive for either
CK 5/6 or EGFR. Nielsen et al [19], who proposed these
criterions in 2004 for invasive breast cancer, found that
defining basal-like breast cancer in this way resulted in
76% sensitivity and 100% specificity, when the gene
expression signature was used as gold standard. Abd
El-Rehim et al., [28] studied over 1000 cases of invasive
breast cancer with 26 IHC markers and identified 6
clusters of tumors. Five of these clusters roughly corre-
sponded to the 5 subtypes identified earlier; the remain-
ing group consisted of only 4 cases. Livasy et al., [18]
then verified and confirmed the criteria in DCIS tumors.
Today, IHC is increasingly used as a surrogate for mole-
cular gene profiling since it allows classification of
tumors at an affordable costs and in the absence of
fresh tissue speciments [29]. Moreover, these four sub-
groups have distinguishing features closely associated
with subtypes defined by gene expression profiling,
including distinct clinical outcomes [30].
A possible cause of subtype misclassification is the
HER2 status based on IHC scoring. We assessed the sta-
tus of HER2 by SISH and used IHC only in those cases
Table 1 Characteristics of DCIS molecular subgroups, by immunohistochemistry in 392 women with a primary DCIS
Characteristics Basal-like (n = 32, 8.2%) Non basal-like (n = 360, 91.8%) P
Age at entry, mean ± SD (n = 392) 56.7 ± 12.6 57.8 ± 11.5 0.6
Tumor size, number (%) (n = 352) 0.84
≤ 15 m 16 (59.3) 175 (53.9)
> 15 mm 8 (29.6) 104 (32.0)
Multifocal 3 (11.1) 46 (14.2)
Tumor grade*, number (%) (n = 388) 0.11
I 1 (3.1) 29 (8.2)
II 11 (34.4) 171 (48.0)
III 20 (62.5) 156 (43.8)
Detection mode, number (%) (n = 391) 0.3
Screening 22 (68.8) 276 (76.9)
Clinically 10 (31.3) 83 (23.1)
Type of surgery, number (%) (n = 392) 0.61
Breast Conserving Surgery 26 (81.3) 272 (75.6)
Mastectomy 6 (18.8) 88 (24.4)
Postoperative radiotherapy, number (%)(n = 392) 0.72
Yes 10 (31.3) 130 (36.1)
No 22 (68.8) 230 (63.9)
* Tumor grade: DCIS were classified according to the European Organization for Research and Treatment of Cancer (EORTC) system.
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especially for the borderline cases scored as 2+ by IHC.
By using both methods we should have minimized the
risk of subtype misclassification.
Our results indicated that the molecular subtypes of
DCIS were not related to basic characteristics as histo-
pathological grade and tumor size. However, many
potential prognostic factors may interact with the choice
of adjuvant therapy [29] and we therefore adjusted for
adjuvant treatment and type of surgery in the analyses.
In this study, no women received chemotherapy or anti-
estrogen. One hundred and forty received postoperative
radiotherapy. The percentage of patients who received
postoperative radiotherapy was fairly evenly distributed
among the groups with different subtype of DCIS. The
type of surgery was also evenly distributed.
Basal-like invasive breast cancer is an entity that is lar-
gely characterized by positive expression of basal CKs
and other genes that are characteristic of basal-like cells
and by high proliferative activity. Basal-like invasive
breast cancer is considered to be associated with poor
prognosis [13] and this supposition has been proved in
many studies [4,5,13,17,33,34]. In our study, we found
about a doubled risk for local recurrence and invasive-
or general recurrences for basal-like DCIS. The higher
risk was not statistically significant but, on the other
hand, it was consistent in the univariate, multivariate
and Kaplan-Meier analyses for all patients and for the
subgroup of patients with BCS. Although we have con-
ducted a population-based study with long follow-up,
we were not able to show a statistically significantly
poorer prognosis for the basal-like DCIS. Like in inva-
sive breast cancer, the basal-like subgroup is small and
this makes the statistical power low and a conclusive
study would have to include a much larger number of
patients. Today, we take nuclear grade, size, necrosis
and margins into consideration when designing adjuvant
treatment after BCS of DCIS according to the Swedish
Table 2 Cox regression analyses by molecular subgroup, by immunohistochemistry
All (n = 392) Breast Conserving Surgery (n = 298)
Univariate HR
(95% CI)
Adjusted* HR
(95% CI)
Univariate HR
(95% CI)
Adjusted* HR
(95% CI)
Event: local recurrence (n = 76)
Gene-expression classification
Non basal-like (n = 360) 1 (Reference) 1 1 1
Basal-like (n = 32) 1.7 (0.8-3.8) 1.9 (0.8-4.2) 1.6 (0.7-3.6) 1.8 (0.7-4.2)
Triple-negative classification
Non triple-negative (n = 377) 1 (Reference) 1 1 1
Triple-negative (n = 32) 1.1 (0.4-2.7) 1.1 (0.4-2.9) 1.0 (0.4-2.7) 1.0 (0.3-2.9)
Tumor grade
I (n = 30) 1 (Reference) 1 1 1
II (n = 182) 1.2 (0.4-3.4) 1.4 (0.5-4.0) 1.3 (0.5-3.9) 1.4 (0.5-3.9)
III (n = 176) 1.0 (0.3-2.9) 1.3 (0.5-3.9) 1.4 (0.5-4.0) 1.4 (0.5-4.2)
Postoperation radiotherapy
No (n = 252) 1 (Reference) 1 1 1
Yes (n = 140) 0.9 (0.5-1.5) 0.7 (0.4-1.3) 0.8 (0.4-1.4) 0.7 (0.4-1.4)
Event: invasive- and general recurrence (n = 47)
Gene-expression classification
Non basal-like (n = 360) 1 (Reference) 1 1 1
Basal-like (n = 32) 2.0 (0.8-5.0) 1.9 (0.7-5.1) 2.2 (0.8-5.6) 2.3 (0.8-6.1)
Triple-negative classification
Non triple-negative (n = 377) 1 (Reference) 1 1 1
Triple-negative (n = 32) 1.4 (0.5-4.0) 1.6 (0.6-4.8) 1.7 (0.6-4.9) 2.1 (0.7-6.3)
Tumor grade
I (n = 30) 1 (Reference) 1 1 1
II (n = 182) 1.0 (0.3-3.3) 1.1 (0.3-3.8) 1.1 (0.3-3.8) 1.1 (0.3-3.8)
III (n = 176) 0.7 (0.2-2.4) 1.1 (0.3-3.9) 0.9 (0.2-3.1) 1.0 (0.3-3.9)
Postoperation radiotherapy
No (n = 252) 1 (Reference) 1 1 1
Yes (n = 140) 0.8 (0.4-1.6) 0.7 (0.3-1.5) 0.7 (0.3-1.4) 0.7 (0.3-1.6)
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Group [35]. In this study, grade did not relate to prog-
nosis (see Table 2) and molecular subtyping by IHC
might indeed be more useful.
We also investigated the prognosis of triple-negative
DCIS. In invasive cancer, triple-negative tumors have
been shown to have a worse prognosis [36-38].
We observed a slightly elevated risk for developing inva-
sive disease, but this was not statistically significant. In
some studies, triple-negative and basal-like DCIS cases
have been considered to haveaf a i r l ys i m i l a rp r o g n o s i s .
In our study, there was a considerable miss-match
between these cases as already described in invasive
breast cancer by others [21,39,40].
Conclusions
In conclusion, basal-like DCIS showed about a doubled,
however not statistically significant risk for local recur-
rence and developing invasive cancer compared with the
other molecular subtypes. In this study, molecular sub-
typing was a better prognostic parameter than histo-
pathological grade.
(a)                                                       (b)  
Figure 1 Kaplan-Meier analyses of local recurrence and invasive- and general recurrence by DCIS molecular subgroup by
immunohistochemistry. (a) Local recurrence (in situ or invasive) in women with a primary DCIS, undergoing breast-conserving surgery (BCS),
by molecular subtype. (b) Invasive- or general recurrence in all women with a primary DCIS by molecular subtype.
(a) (b)
Figure 2 Kaplan-Meier analysis of local recurrence and invasive- and general recurrence by triple-negative and non triple-negative
DCIS. (a) Local recurrence (BCS), triple negative DCIS vs. non-triple negative DCIS. (b) Invasive- or general recurrence in all women, triple
negative DCIS vs. non-triple negative DCIS.
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